In addition, the antibody-drug conjugate (ADC) DFRF4539A targeting FcRH5 has demonstrated appreciable anti-MM efficacy in xenograft models17, but unexpectedly, showed limited clinical benefit in the phase-I trial recruiting RRMM patients20. Here, FCRL5 is linked to Miyoshi myopathy.